Profile data is unavailable for this security.
About the company
Photocure ASA is a Norway-based company active in the pharmaceutical industry. The Company is focused on developing and improving photodynamic technology and owns a Photocure Technology platform, which develops photodynamic technology for diagnosis and therapy. Based on the Photocure Technology platform, Photocure has developed and commercialized Hexvix (Hyperthermic IntraVEsical Chemotherapy) and Cysview (hexaminolevulinate HCL) for use in bladder cancer. The Company’s activities are divided into two business segments: The Commercial Franchise and The Development Portfolio. The Commercial Franchise segment includes Hexvix/Cysview by geography (U.S. and Europe) and other sales (partners and other products including sales revenues for Hivec). The Development Portfolio segment includes development of pipeline products.
- Revenue in NOK (TTM)513.58m
- Net income in NOK12.84m
- Incorporated1995
- Employees102.00
- LocationPhotocure ASAHoffsveien 4OSLO 0275NorwayNOR
- Phone+47 22062210
- Fax+47 22062218
- Websitehttps://photocure.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lipum AB (publ) | 0.00 | -40.17m | 314.85m | 5.00 | -- | 6.44 | -- | -- | -3.17 | -3.17 | 0.00 | 2.25 | 0.00 | -- | -- | 0.00 | -92.41 | -127.85 | -120.33 | -184.50 | -- | -- | -- | -293,228.70 | -- | -328.75 | 0.1979 | -- | -- | -- | 2.38 | -- | -- | -- |
| Dicot Pharma AB | 238.60k | -52.15m | 382.37m | 3.00 | -- | 13.38 | -- | 1,602.57 | -0.0505 | -0.0505 | 0.0002 | 0.0157 | 0.0054 | 9.26 | 0.079 | 77,696.66 | -117.97 | -- | -144.43 | -- | -19,313.23 | -- | -21,855.92 | -- | 1.98 | -- | 0.00 | -- | 89.43 | -- | -39.05 | -- | -- | -- |
| Orexo AB | 609.88m | -107.79m | 387.28m | 113.00 | -- | -- | -- | 0.635 | -3.05 | -3.05 | 17.28 | -0.7896 | 0.7609 | 1.17 | 2.32 | 5,136,207.00 | -13.45 | -6.41 | -20.81 | -9.99 | 88.28 | 86.76 | -17.67 | -11.83 | 1.47 | -0.7557 | 1.05 | -- | 2.32 | -3.99 | 27.76 | -- | 25.77 | -- |
| Navamedic ASA | 543.49m | 24.64m | 406.24m | 45.00 | 16.49 | 1.64 | 10.19 | 0.7475 | 1.39 | 1.39 | 31.30 | 14.00 | 1.08 | 3.60 | 4.21 | 12,077,510.00 | 4.91 | 0.039 | 7.35 | 0.0635 | 40.04 | 38.33 | 4.53 | 0.038 | 0.8753 | 3.63 | 0.3686 | -- | 33.98 | 22.72 | -88.77 | -2.53 | 59.60 | -- |
| Enzymatica AB (publ) | 46.01m | -57.27m | 447.25m | 16.00 | -- | 4.80 | -- | 9.72 | -0.309 | -0.309 | 0.2485 | 0.3747 | 0.3461 | 1.19 | 8.20 | 2,497,333.00 | -43.08 | -27.36 | -45.77 | -33.98 | 63.99 | 65.08 | -124.47 | -66.12 | -- | -24.43 | 0.2789 | -- | 4.00 | -0.6382 | 27.57 | -- | 7.02 | -- |
| Infant Bacterial Therapeutics AB | 0.00 | -145.63m | 515.70m | 9.00 | -- | 2.20 | -- | -- | -10.57 | -10.57 | 0.00 | 17.57 | 0.00 | -- | -- | 0.00 | -46.35 | -16.11 | -54.97 | -16.69 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -88.03 | -- | -- | -- |
| Isofol Medical AB (publ) | 0.00 | -35.52m | 578.66m | 3.00 | -- | 5.55 | -- | -- | -0.2164 | -0.2164 | 0.00 | 0.6309 | 0.00 | -- | -- | 0.00 | -24.29 | -66.73 | -28.91 | -88.27 | -- | -- | -- | -1,023.62 | -- | -- | 0.00 | -- | -94.37 | -- | 76.80 | -- | -- | -- |
| Moberg Pharma AB (publ) | 5.05m | -23.29m | 629.79m | 9.00 | -- | 0.6339 | -- | 124.82 | -0.9608 | -0.9608 | 0.1936 | 20.27 | 0.0065 | -- | 0.4949 | -- | -3.02 | -- | -3.12 | -- | 65.19 | -- | -461.64 | -- | 12.32 | -- | 0.0043 | -- | -100.00 | -- | -34.26 | -- | -- | -- |
| Magle Chemoswed Holding AB | 211.06m | 17.14m | 685.66m | 78.00 | 23.48 | 0.8069 | 16.85 | 3.25 | 1.55 | 1.55 | 19.09 | 45.11 | 0.365 | 0.3327 | 8.15 | 2,643,474.00 | 2.96 | 2.52 | 3.92 | 3.52 | 88.98 | 85.67 | 8.12 | 3.92 | 0.4894 | 4.19 | 0.2994 | -- | 17.00 | 9.97 | 33.07 | -- | -6.34 | -- |
| IRLAB Therapeutics AB | 51.81m | -115.38m | 739.52m | 32.00 | -- | 19.03 | -- | 14.27 | -2.17 | -2.17 | 0.9759 | 0.7332 | 0.2916 | -- | 3.58 | 1,946,769.00 | -64.93 | -27.12 | -118.29 | -30.42 | -138.17 | -72.18 | -222.69 | -155.57 | -- | -21.72 | 0.6132 | -- | -90.71 | 216.07 | -56.82 | -- | -22.56 | -- |
| Vistin Pharma ASA | 423.59m | 61.37m | 1.18bn | 77.00 | 19.22 | 3.80 | 14.69 | 2.78 | 1.38 | 1.38 | 9.55 | 7.01 | 1.09 | 1.89 | 7.27 | 5,501,130.00 | 15.85 | 1.73 | 19.26 | 2.11 | 64.84 | 58.92 | 14.49 | 2.36 | 1.06 | 21.05 | 0.0178 | 222.57 | 51.35 | 16.95 | 1,066.84 | -- | -0.1922 | -- |
| Photocure ASA | 513.58m | 12.84m | 1.44bn | 102.00 | 114.30 | 2.89 | 34.53 | 2.81 | 0.4655 | 0.4655 | 18.98 | 18.43 | 0.7233 | 0.8802 | 7.86 | 5,035,059.00 | 1.81 | -3.06 | 2.01 | -3.54 | 94.52 | 93.64 | 2.50 | -5.15 | 5.30 | -- | 0.00 | -- | 27.35 | 22.50 | 101.36 | -- | 49.83 | -- |
Data as of Nov 05 2024. Currency figures normalised to Photocure ASA's reporting currency: Norwegian Krone NOK
36.76%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Briarwood Chase Management LLCas of 04 May 2023 | 3.86m | 14.23% |
| Lannebo Fonder ABas of 04 May 2023 | 1.79m | 6.62% |
| SEB Investment Management ABas of 29 Sep 2023 | 1.34m | 4.93% |
| Handelsbanken Fonder ABas of 30 Sep 2024 | 787.50k | 2.90% |
| MP Pensjon PKas of 31 Dec 2023 | 661.09k | 2.44% |
| Equinor Asset Management ASAas of 28 Jun 2024 | 408.57k | 1.51% |
| KLP Kapitalforvaltning ASas of 30 Sep 2024 | 375.63k | 1.39% |
| Nordnet Livsforsikring ASas of 31 Dec 2023 | 257.58k | 0.95% |
| DNB Asset Management ASas of 30 Aug 2024 | 257.11k | 0.95% |
| Mandarine Gestion SAas of 29 Feb 2024 | 232.90k | 0.86% |
More ▼
Data from 20 May 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
